Journals / Acta Medica Alanya / 2021 / Cilt: 5 - Sayı: 2

Antibacterial effects of leukocyte and platelet-rich fibrin against Escherichia coli and Enterococcus faecalis

Lökosit ve Trombositten Zengin Fibrinin Escherichia Coli’ye ve Enterococcus Faecalis'e Karşı Antibakteriyel Etkileri

Pages
132–137
Publication Date
2022-09-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antibacterial activity of L-PRF against E. coli and E. faecalis ATCC standardstrains was analyzed using the Kirby Bauer disk diffusion method.Results: The inhibition zones with PRF had not been detected even though theresults obtained using control discs were in accordance with the expectations.Conclusion: L-PRF demonstrated no inhibition zone against E. coli and E. faecalis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The main goal of this research was to explore the in-vitro antibacterialcharacteristics of leukocyte and platelet-rich fibrin (L-PRF) against Escherichia coli(E.
📊
Key Findings & Data:Faecalis).Materials and methods: The study was conducted on 21 patients (10 females,11 males, age range 21-32 years).
💡
Conclusion & Impact:Antibacterial activity of L-PRF against E. coli and E. faecalis ATCC standardstrains was analyzed using the Kirby Bauer disk diffusion method.Results: The inhibition zones with PRF had not been detected even though theresults obtained using control discs were in accordance with the expectations.Conclusion: L-PRF demonstrated no inhibition zone against E. coli and E. faecalis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The main goal of this research was to explore the in-vitro antibacterialcharacteristics of leukocyte and platelet-rich fibrin (L-PRF) against Escherichia coli(E. Coli) and Enterococcus faecalis (E. Faecalis).Materials and methods: The study was conducted on 21 patients (10 females,11 males, age range 21-32 years). L-PRF was prepared from the participants’ ownblood. Antibacterial activity of L-PRF against E. coli and E. faecalis ATCC standardstrains was analyzed using the Kirby Bauer disk diffusion method.Results: The inhibition zones with PRF had not been detected even though theresults obtained using control discs were in accordance with the expectations.Conclusion: L-PRF demonstrated no inhibition zone against E. coli and E. faecalis.

Özet

Amaç: Bu çalışmanın amacı, lökosit ve trombositten zengin fibrinin (TZF) Escherichia coli’ye (E. Coli) ve Enterococcus faecalis'e (E. Faecalis) karşı in vitro antibakteriyel etkilerini araştırmaktır. Gereç ve yöntemler: Çalışma 21 hasta (10 kadın, 11 erkek, yaş aralığı 21-32 yaş) üzerinde yürütülmüştür. Katılımcılardan elde edilen kan örnekleri kullanılarak TZF hazırlanmıştır. TZF'nin E. coli ve E. faecalis ATCC standart suşlarına antibakteriyel aktivitesi Kirby Bauer disk difüzyon yöntemi kullanılarak test edilmiştir. Bulgular: Beklenen sonuçlar kontrol diski ile elde edilmesine rağmen, TZF’nin değerlendirilen bakterilere karşı inhibisyon zonu göstermediği tespit edilmiştir Sonuç: TZF, E.coli’ye ve E. faecalis’e karşı inhibisyon bölgesi göstermemiştir.

🔖

Cite This Article

ÇETİN, M. B., SEZGİN, Y., BULUT, Ş., EVREN, E. (2022). Antibacterial effects of leukocyte and platelet-rich fibrin against Escherichia coli and Enterococcus faecalis. Acta Medica Alanya, Cilt: 5 - Sayı: 2, 132–137. https://ajindex.com/articles/425784

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Moraschini V, Barboza Edos S. Use of Platelet-Rich Fibrin Membrane in the Treatment of Gingival Recession: A Systematic Review and Meta-Analysis. J Periodontol. 2016
  2. PMID: 26561997 2. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al., Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006
  3. e37-44. PMID: 16504849 3. Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. J Periodontol. 2010
  4. PMID: 20373539 4. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009
  5. PMID: 19089687 5. Panda S, Doraiswamy J, Malaiappan S, Varghese SS, Del Fabbro M. Additive effect of autologous platelet concentrates in treatment of intrabony defects: a systematic review and meta-analysis. J Investig Clin Dent. 2016
  6. PMID: 25048153 6. Li Q, Pan S, Dangaria SJ, Gopinathan G, Kolokythas A, Chu S, et al., Platelet-rich fibrin promotes periodontal regeneration and enhances alveolar bone augmentation. Biomed Res Int. 2013
  7. 638043. PMID: 23586051 7. Su NY, Yang LC, Chang YC. Platelet-rich fibrin is the first-line treatment option for periodontal regeneration. J Dent Sci. 2017
  8. PMID:30895051 8. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J. 2014
  9. PMID: 24932440 9. Fabbro MD, Bortolin M, Taschieri S, Ceci C, Weinstein RL. Antimicrobial properties of platelet-rich preparations. A systematic review of the current pre-clinical evidence. Platelets. 2016
  10. PMID: 26763769 10. Drago L, Bortolin M, Vassena C, Taschieri S, Del Fabbro M. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol. 2013
  11. PMID: 23442413 11. Yang LC, Hu SW, Yan M, Yang JJ, Tsou SH, Lin YY. Antimicrobial Activity of Platelet-Rich Plasma and Other Plasma Preparations Against